{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:14:47Z","timestamp":1787242487367,"version":"build-2736575974"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013268","name":"Directorate-General for Justice and Consumers","doi-asserted-by":"publisher","award":["Grant No. 957776"],"award-info":[{"award-number":["Grant No. 957776"]}],"id":[{"id":"10.13039\/100013268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40263-024-01101-3","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:08:31Z","timestamp":1721491711000},"page":"771-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-6196","authenticated-orcid":false,"given":"Anton","family":"Gomez-Escolar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-2955","authenticated-orcid":false,"given":"Daniel","family":"Folch-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Stefaniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-1618","authenticated-orcid":false,"given":"Zoe","family":"Swithenbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-5942","authenticated-orcid":false,"given":"Andreia","family":"Nisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6755-4567","authenticated-orcid":false,"given":"Fleur","family":"Braddick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-1252","authenticated-orcid":false,"given":"Nazish","family":"Idrees Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8906","authenticated-orcid":false,"given":"Pim B.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-5121","authenticated-orcid":false,"given":"Albert","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"1101_CR1","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2023. Vienna: United Nations; 2023."},{"issue":"8","key":"1101_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1176\/appi.ajp.2018.17101174","volume":"175","author":"ND Volkow","year":"2018","unstructured":"Volkow ND, Boyle M. Neuroscience of addiction: relevance to prevention and treatment. Am J Psychiatry. 2018;175(8):729\u201340. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17101174.","journal-title":"Am J Psychiatry"},{"key":"1101_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.clinpsy.3.022806.091455","volume":"3","author":"TH Brandon","year":"2007","unstructured":"Brandon TH, Vidrine JI, Litvin EB. Relapse and relapse prevention. Annu Rev Clin Psychol. 2007;3:257\u201384. https:\/\/doi.org\/10.1146\/annurev.clinpsy.3.022806.091455.","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"1101_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jsat.2004.12.005","volume":"28","author":"R Dodge","year":"2005","unstructured":"Dodge R, Sindelar J, Sinha R. The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment. J Subst Abuse Treat. 2005;28(2):189\u201396. https:\/\/doi.org\/10.1016\/j.jsat.2004.12.005.","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"1101_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"GBD 2016 Alcohol and Drug Use Collaborators","year":"2018","unstructured":"GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012. https:\/\/doi.org\/10.1016\/S2215-0366(18)30337-7.","journal-title":"Lancet Psychiatry"},{"key":"1101_CR6","doi-asserted-by":"publisher","unstructured":"GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397(10292):2337-2360. https:\/\/doi.org\/10.1016\/S0140-6736(21)01169-7.","DOI":"10.1016\/S0140-6736(21)01169-7"},{"key":"1101_CR7","unstructured":"Drake RE, Mueser KT, Brunette MF. Management of persons with co-occurring severe mental illness and substance use disorder: program implications. World Psychiatry. 2007;6(3):131\u20136."},{"issue":"2","key":"1101_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350. https:\/\/doi.org\/10.1016\/S2215-0366(21)00395-3.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1101_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11920-019-0997-0","volume":"21","author":"J Rehm","year":"2019","unstructured":"Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21(1):10. https:\/\/doi.org\/10.1007\/s11920-019-0997-0.","journal-title":"Curr Psychiatry Rep"},{"key":"1101_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388. https:\/\/doi.org\/10.2147\/PPA.S29716.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"1101_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.mp.4001852","volume":"11","author":"A Bystritsky","year":"2006","unstructured":"Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805\u201314. https:\/\/doi.org\/10.1038\/sj.mp.4001852.","journal-title":"Mol Psychiatry"},{"key":"1101_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.994425","volume":"13","author":"A Pandey","year":"2022","unstructured":"Pandey A, Kalita KN. Treatment-resistant schizophrenia: how far have we traveled? Front Psychiatry. 2022;13:994425. https:\/\/doi.org\/10.3389\/fpsyt.2022.994425.","journal-title":"Front Psychiatry"},{"key":"1101_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","volume":"10","author":"JJ Fuentes","year":"2019","unstructured":"Fuentes JJ, Fonseca F, Elices M, Farr\u00e9 M, Torrens M. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psychiatry. 2019;10:943. https:\/\/doi.org\/10.3389\/fpsyt.2019.00943.","journal-title":"Front Psychiatry"},{"issue":"2","key":"1101_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1101_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/S0033291721004207","volume":"52","author":"W Hall","year":"2022","unstructured":"Hall W. Why was early therapeutic research on psychedelic drugs abandoned? Psychol Med. 2022;52(1):26\u201331. https:\/\/doi.org\/10.1017\/S0033291721004207.","journal-title":"Psychol Med"},{"issue":"1","key":"1101_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2004.04.011","volume":"76","author":"JF Spillane","year":"2004","unstructured":"Spillane JF. Debating the controlled substances act. Drug Alcohol Depend. 2004;76(1):17\u201329. https:\/\/doi.org\/10.1016\/j.drugalcdep.2004.04.011.","journal-title":"Drug Alcohol Depend"},{"key":"1101_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109399","volume":"226","author":"M Marks","year":"2023","unstructured":"Marks M. The varieties of psychedelic law. Neuropharmacology. 2023;226:109399. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109399.","journal-title":"Neuropharmacology"},{"issue":"18","key":"1101_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2206443.","journal-title":"N Engl J Med"},{"issue":"10","key":"1101_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79(10):953-62.\u00a0https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096.","journal-title":"JAMA Psychiat"},{"issue":"11","key":"1101_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392. https:\/\/doi.org\/10.1177\/0269881114548296.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1101_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jama.2021.12481","volume":"326","author":"WR Smith","year":"2021","unstructured":"Smith WR, Appelbaum PS. Two models of legalization of psychedelic substances: reasons for concern. JAMA. 2021;326(7):697\u20138. https:\/\/doi.org\/10.1001\/jama.2021.12481.","journal-title":"JAMA"},{"key":"1101_CR22","volume-title":"Medical use of cannabis and cannabinoids: questions and answers for policymaking","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2018","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Publications Office of the European Union, Luxembourg.\u00a02018.\u00a0https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/10171\/20185584_TD0618186ENN_PDF.pdf"},{"key":"1101_CR23","unstructured":"Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Therapeutic Goods Administration (TGA). 2023. https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists. Accessed 28 Feb 2023."},{"key":"1101_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","volume":"619","author":"R Haridy","year":"2023","unstructured":"Haridy R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023;619:227\u20138. https:\/\/doi.org\/10.1038\/d41586-023-02093-8.","journal-title":"Nature"},{"issue":"1","key":"1101_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiat. 2023;80(1):77\u201383. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.4101.","journal-title":"JAMA Psychiat"},{"key":"1101_CR26","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000751","volume":"29","author":"C Gastaldon","year":"2019","unstructured":"Gastaldon C, Papola D, Ostuzzi G, Barbui C. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiol Psychiatr Sci. 2019;29:e79. https:\/\/doi.org\/10.1017\/S2045796019000751.","journal-title":"Epidemiol Psychiatr Sci."},{"key":"1101_CR27","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380. https:\/\/doi.org\/10.1038\/s41591-023-02565-4.","journal-title":"Nat Med"},{"issue":"3","key":"1101_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/02791072.2016.1188225","volume":"48","author":"AA Nunes","year":"2016","unstructured":"Nunes AA, Dos Santos RG, Os\u00f3rio FL, Sanches RF, Crippa JAS, Hallak JEC. Effects of ayahuasca and its alkaloids on drug dependence: a systematic literature review of quantitative studies in animals and humans. J Psychoactive Drugs. 2016;48(3):195\u2013205. https:\/\/doi.org\/10.1080\/02791072.2016.1188225.","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"1101_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13229","volume":"27","author":"J Calleja-Conde","year":"2022","unstructured":"Calleja-Conde J, Morales-Garc\u00eda JA, Echeverry-Alzate V, B\u00fchler KM, Gin\u00e9 E, L\u00f3pez-Moreno JA. Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies. Addict Biol. 2022;27(6):e13229. https:\/\/doi.org\/10.1111\/adb.13229.","journal-title":"Addict Biol"},{"issue":"5","key":"1101_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","volume":"41","author":"D De Gregorio","year":"2021","unstructured":"De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, et al. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, mdma, and ketamine. J Neurosci. 2021;41(5):891\u2013900. https:\/\/doi.org\/10.1523\/JNEUROSCI.1659-20.2020.","journal-title":"J Neurosci"},{"key":"1101_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733. https:\/\/doi.org\/10.3389\/fphar.2018.00733.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1101_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"key":"1101_CR33","doi-asserted-by":"publisher","unstructured":"Grof S. Revision and re-enchantment of psychology: legacy from half a century of consciousness research. The Wiley-Blackwell Handbook of Transpersonal Psychology. Chichester, UK: John Wiley & Sons, Ltd; 2013. p. 89\u2013120. https:\/\/doi.org\/10.1002\/9781118591277.ch5.","DOI":"10.1002\/9781118591277.ch5"},{"issue":"16","key":"1101_CR34","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-44.e4. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008.","journal-title":"Neuron"},{"issue":"3","key":"1101_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399. https:\/\/doi.org\/10.1177\/0269881114565144.","journal-title":"J Psychopharmacol"},{"key":"1101_CR36","unstructured":"Rydzy\u0144ski Z, Cwynar S, Grzelak L, Jagiello W. Preliminary report on the experience with psychosomimetic drugs in the treatment of alcoholism. Act Nerv Super (Praha). 1968;10(3):273."},{"key":"1101_CR37","unstructured":"Rydzy\u0144ski Z, Gruszczy\u0144ski W. Treatment of alcoholism with psychotomimetic drugs: A follow-up study. Act Nerv Super (Praha). 1978;20(2):81\u20132."},{"issue":"1","key":"1101_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"1101_CR39","doi-asserted-by":"publisher","first-page":"9333","DOI":"10.1038\/s41598-019-45812-w","volume":"9","author":"JG Dean","year":"2019","unstructured":"Dean JG, Liu T, Huff S, Sheler B, Barker SA, Strassman RJ, et al. Biosynthesis and extracellular concentrations of N, N-dimethyltryptamine (DMT) in mammalian brain. Sci Rep. 2019;9(1):9333. https:\/\/doi.org\/10.1038\/s41598-019-45812-w.","journal-title":"Sci Rep"},{"issue":"11","key":"1101_CR40","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170\u201382. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022.","journal-title":"Cell Rep"},{"issue":"6","key":"1101_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1590\/1516-4446-2020-0884","volume":"42","author":"S Ruffell","year":"2020","unstructured":"Ruffell S, Netzband N, Bird C, Young AH, Juruena MF. The pharmacological interaction of compounds in ayahuasca: a systematic review. Braz J Psychiatry. 2020;42(6):646\u201356. https:\/\/doi.org\/10.1590\/1516-4446-2020-0884.","journal-title":"Braz J Psychiatry."},{"issue":"4","key":"1101_CR42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655\u201363. https:\/\/doi.org\/10.1017\/S0033291718001356.","journal-title":"Psychol Med"},{"issue":"1","key":"1101_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima OF, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36(1):77\u201381. https:\/\/doi.org\/10.1097\/JCP.0000000000000436.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1101_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/JCP.0000000000001428","volume":"41","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, de Os\u00f3rio FL, Rocha JM, Rossi GN, Bouso JC, Rodrigues LS, et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2021;41(5):540\u201350. https:\/\/doi.org\/10.1097\/JCP.0000000000001428.","journal-title":"J Clin Psychopharmacol"},{"key":"1101_CR45","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00213-019-05446-2","volume":"237","author":"D Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez D, Cantillo J, P\u00e9rez I, Farr\u00e9 M, Feilding A, Obiols JE, et al. Therapeutic potential of ayahuasca in grief: a prospective, observational study. Psychopharmacology. 2020;237:1171\u201382. https:\/\/doi.org\/10.1007\/s00213-019-05446-2.","journal-title":"Psychopharmacology"},{"key":"1101_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00406-021-01267-7","volume":"272","author":"LS Rodrigues","year":"2022","unstructured":"Rodrigues LS, Rossi GN, Rocha JM, Os\u00f3rio LF, Bouso JC, Hallak JEC, et al. Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016\u20132020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci. 2022;272:541\u201356. https:\/\/doi.org\/10.1007\/s00406-021-01267-7.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"1101_CR47","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated Gq-coupled 5-HT serotonin receptor. Cell. 2020;182(6):1574-88.e19. https:\/\/doi.org\/10.1016\/j.cell.2020.08.024.","journal-title":"Cell"},{"issue":"7","key":"1101_CR48","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen P-\u00d8. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1101_CR49","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","volume":"28","author":"C Savage","year":"1973","unstructured":"Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry. 1973;28(6):808\u201314. https:\/\/doi.org\/10.1001\/archpsyc.1973.01750360040005.","journal-title":"Arch Gen Psychiatry"},{"key":"1101_CR50","doi-asserted-by":"crossref","unstructured":"Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469\u201382. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5970697","DOI":"10.15288\/qjsa.1966.27.469"},{"issue":"10","key":"1101_CR51","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","volume":"125","author":"LE Hollister","year":"1969","unstructured":"Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969;125(10):1352\u20137. https:\/\/doi.org\/10.1176\/ajp.125.10.1352.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1101_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1176\/ajp.126.1.59","volume":"126","author":"A Ludwig","year":"1969","unstructured":"Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59\u201369. https:\/\/doi.org\/10.1176\/ajp.126.1.59.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1101_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","volume":"150","author":"WT Bowen","year":"1970","unstructured":"Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150(2):111\u20138. https:\/\/doi.org\/10.1097\/00005053-197002000-00003.","journal-title":"J Nerv Ment Dis"},{"key":"1101_CR54","unstructured":"Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. Int Z Klin Pharmakol Ther Toxikol. 1971;4(4):446\u201354."},{"key":"1101_CR55","doi-asserted-by":"crossref","unstructured":"Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol. 1970;31(4):932\u201349.","DOI":"10.15288\/qjsa.1970.31.932"},{"key":"1101_CR56","doi-asserted-by":"publisher","unstructured":"Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, et al. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Sci Transl Med. 2019;11(522). https:\/\/doi.org\/10.1126\/scitranslmed.aaw6435.","DOI":"10.1126\/scitranslmed.aaw6435"},{"key":"1101_CR57","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","volume":"57","author":"P Kamilar-Britt","year":"2015","unstructured":"Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci Biobehav Rev. 2015;57:433\u201346. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.08.016.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1101_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","volume":"35","author":"B Sessa","year":"2021","unstructured":"Sessa B, Higbed L, O\u2019Brien S, Durant C, Sakal C, Titheradge D, et al. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol. 2021;35(4):375\u201383. https:\/\/doi.org\/10.1177\/0269881121991792.","journal-title":"J Psychopharmacol"},{"key":"1101_CR59","doi-asserted-by":"publisher","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus (Am Psychiatr Publ). 2023;21(3):315\u201328. https:\/\/doi.org\/10.1176\/appi.focus.23021011.","DOI":"10.1176\/appi.focus.23021011"},{"key":"1101_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109356","volume":"233","author":"CR Nicholas","year":"2022","unstructured":"Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022;233:109356. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109356.","journal-title":"Drug Alcohol Depend"},{"key":"1101_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I Ivan Ezquerra-Romano","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72\u201382. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1101_CR62","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1061","volume":"8","author":"Z Walsh","year":"2021","unstructured":"Walsh Z, Mollaahmetoglu OM, Rootman J, Golsof S, Keeler J, Marsh B, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021;8(1):e19. https:\/\/doi.org\/10.1192\/bjo.2021.1061.","journal-title":"BJPsych Open."},{"key":"1101_CR63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","volume":"9","author":"JL Jones","year":"2018","unstructured":"Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277. https:\/\/doi.org\/10.3389\/fpsyt.2018.00277.","journal-title":"Front Psychiatry."},{"key":"1101_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2016.39","volume":"22","author":"E Dakwar","year":"2017","unstructured":"Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Mol Psychiatry. 2017;22:76\u201381. https:\/\/doi.org\/10.1038\/mp.2016.39.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1101_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","volume":"76","author":"E Dakwar","year":"2014","unstructured":"Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. 2014;76(1):40\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2013.08.009.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1101_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0740-5472(02)00275-1","volume":"23","author":"E Krupitsky","year":"2002","unstructured":"Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23(4):273\u201383. https:\/\/doi.org\/10.1016\/s0740-5472(02)00275-1.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1101_CR67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","volume":"39","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13\u20139. https:\/\/doi.org\/10.1080\/02791072.2007.10399860.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"1101_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","volume":"177","author":"E Dakwar","year":"2020","unstructured":"Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125\u201333. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19070684.","journal-title":"Am J Psychiatry"},{"key":"1101_CR69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","volume":"151","author":"TT Le","year":"2022","unstructured":"Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J Psychiatr Res. 2022;151:476\u201396. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.035.","journal-title":"J Psychiatr Res"},{"key":"1101_CR70","unstructured":"Jovaisa T, Laurinenas G, Vosylius S, Sipylaite J, Badaras R, Ivaskevicius J. Effects of ketamine on precipitated opiate withdrawal. Medicina. 2006;42(8):625\u201334."},{"issue":"2","key":"1101_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","volume":"29","author":"EM Krupitsky","year":"1997","unstructured":"Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165\u201383. https:\/\/doi.org\/10.1080\/02791072.1997.10400185.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"1101_CR72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","volume":"179","author":"M Grabski","year":"2022","unstructured":"Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21030277.","journal-title":"Am J Psychiatry"},{"key":"1101_CR73","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","volume":"242","author":"JM Corkery","year":"2018","unstructured":"Corkery JM. Ibogaine as a treatment for substance misuse: potential benefits and practical dangers. Prog Brain Res. 2018;242:217\u201357. https:\/\/doi.org\/10.1016\/bs.pbr.2018.08.005.","journal-title":"Prog Brain Res"},{"key":"1101_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108717","volume":"138","author":"P K\u00f6ck","year":"2022","unstructured":"K\u00f6ck P, Froelich K, Walter M, Lang U, D\u00fcrsteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022;138: 108717. https:\/\/doi.org\/10.1016\/j.jsat.2021.108717.","journal-title":"J Subst Abuse Treat"},{"key":"1101_CR75","first-page":"003","volume":"1","author":"PL Prior","year":"2014","unstructured":"Prior PL, Prior SL. Ibogaine effect on cocaine craving and use in dependent patients: a double-blind, placebo-controlled pilot study. J Add Ther. 2014;1:003.","journal-title":"J Add Ther."},{"issue":"6","key":"1101_CR76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/cpdd.254","volume":"5","author":"P Glue","year":"2016","unstructured":"Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Hung N, et al. ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin Pharmacol Drug Dev. 2016;5(6):460\u20138. https:\/\/doi.org\/10.1002\/cpdd.254.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1101_CR77","doi-asserted-by":"publisher","unstructured":"Geoffroy P, Wilcox H. Safety, pharmacokinetic, and pharmacodynamic evaluation of a noribogaine multiple-dose regimen in opioid-dependent subjects. Am J Addict. Conference: 27th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry, AAAP 2017. 2017;26(3):245-6. https:\/\/doi.org\/10.1002\/central\/CN-01364501\/full.","DOI":"10.1002\/central\/CN-01364501\/full"},{"issue":"1","key":"1101_CR78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","volume":"914","author":"DC Mash","year":"2000","unstructured":"Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914(1):394\u2013401. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05213.x.","journal-title":"Ann N Y Acad Sci"},{"key":"1101_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0099-9598(01)56012-5","volume":"56","author":"DC Mash","year":"2001","unstructured":"Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155\u201371. https:\/\/doi.org\/10.1016\/s0099-9598(01)56012-5.","journal-title":"Alkaloids Chem Biol"},{"key":"1101_CR80","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fphar.2018.00529","volume":"9","author":"DC Mash","year":"2018","unstructured":"Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Front Pharmacol. 2018;9:529. https:\/\/doi.org\/10.3389\/fphar.2018.00529.","journal-title":"Front Pharmacol"},{"key":"1101_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0099-9598(01)56005-8","volume":"56","author":"KR Alper","year":"2001","unstructured":"Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001;56:1\u201338. https:\/\/doi.org\/10.1016\/s0099-9598(01)56005-8.","journal-title":"Alkaloids Chem Biol"},{"issue":"3","key":"1101_CR82","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372. https:\/\/doi.org\/10.1177\/02698811211069100.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1101_CR83","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/02791072.2022.2039815","volume":"55","author":"KO St Arnaud","year":"2023","unstructured":"St Arnaud KO, Sharpe D. Contextual parameters associated with positive and negative mental health in recreational psychedelic users. J Psychoactive Drugs. 2023;55(1):30\u20139. https:\/\/doi.org\/10.1080\/02791072.2022.2039815.","journal-title":"J Psychoactive Drugs"},{"key":"1101_CR84","unstructured":"Slikker W Jr, Paule MG, Wang C. Handbook of developmental neurotoxicology. Academic Press; 2018."},{"key":"1101_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.672526","volume":"15","author":"D Choudhury","year":"2021","unstructured":"Choudhury D, Autry AE, Tolias KF, Krishnan V. Ketamine: neuroprotective or neurotoxic? Front Neurosci. 2021;15: 672526. https:\/\/doi.org\/10.3389\/fnins.2021.672526.","journal-title":"Front Neurosci"},{"issue":"10","key":"1101_CR86","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1021\/acschemneuro.8b00294","volume":"9","author":"MJ Wasko","year":"2018","unstructured":"Wasko MJ, Witt-Enderby PA, Surratt CK. DARK classics in chemical neuroscience: ibogaine. ACS Chem Neurosci. 2018;9(10):2475\u201383. https:\/\/doi.org\/10.1021\/acschemneuro.8b00294.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"1101_CR87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1360-0443.2006.01314.x","volume":"101","author":"E Gouzoulis-Mayfrank","year":"2006","unstructured":"Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction. 2006;101(3):348\u201361. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01314.x.","journal-title":"Addiction"},{"issue":"4","key":"1101_CR88","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1192\/bjp.bp.108.050344","volume":"194","author":"S Selvaraj","year":"2009","unstructured":"Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P, et al. Brain serotonin transporter binding in former users of MDMA (\u2018ecstasy\u2019). Br J Psychiatry. 2009;194(4):355\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.108.050344.","journal-title":"Br J Psychiatry"},{"issue":"8","key":"1101_CR89","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.neubiorev.2013.04.016","volume":"37","author":"AC Parrott","year":"2013","unstructured":"Parrott AC. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational \u201cecstasy\u201d users. Neurosci Biobehav Rev. 2013;37(8):1466\u201384. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.04.016.","journal-title":"Neurosci Biobehav Rev"},{"key":"1101_CR90","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.neubiorev.2017.07.015","volume":"84","author":"CA Roberts","year":"2018","unstructured":"Roberts CA, Quednow BB, Montgomery C, Parrott AC. MDMA and brain activity during neurocognitive performance: an overview of neuroimaging studies with abstinent \u201cecstasy\u201d users. Neurosci Biobehav Rev. 2018;84:470\u201382. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.07.015.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1101_CR91","doi-asserted-by":"publisher","first-page":"381","DOI":"10.32598\/bcn.9.10.485","volume":"11","author":"NS Mustafa","year":"2020","unstructured":"Mustafa NS, Bakar NHA, Mohamad N, Adnan LHM, Fauzi NFAM, Thoarlim A, et al. MDMA and the brain: a short review on the role of neurotransmitters in neurotoxicity. Basic Clin Neurosci. 2020;11(4):381\u20138. https:\/\/doi.org\/10.32598\/bcn.9.10.485.","journal-title":"Basic Clin Neurosci."},{"issue":"1","key":"1101_CR92","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biopsych.2010.08.030","volume":"69","author":"Y Liao","year":"2011","unstructured":"Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H, et al. Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry. 2011;69(1):42\u20138. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.030.","journal-title":"Biol Psychiatry"},{"key":"1101_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnana.2013.00023","volume":"7","author":"C Wang","year":"2013","unstructured":"Wang C, Zheng D, Xu J, Lam W, Yew DT. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat. 2013;7:23. https:\/\/doi.org\/10.3389\/fnana.2013.00023.","journal-title":"Front Neuroanat"},{"issue":"10","key":"1101_CR94","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022;47(10):1854\u201362. https:\/\/doi.org\/10.1038\/s41386-022-01344-y.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"1101_CR95","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/jcp.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340. https:\/\/doi.org\/10.4088\/jcp.v67n1110.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1101_CR96","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100\u201317. https:\/\/doi.org\/10.1177\/02698811221116926.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1101_CR97","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen CA, Rosenberg H. A review of the acute subjective effects of MDMA\/ecstasy. Addiction. 2006;101(7):933\u201347. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01423.x.","journal-title":"Addiction"},{"issue":"6","key":"1101_CR98","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1101_CR99","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/jcph.1573","volume":"60","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Surman P, Lam F, Hung N, Hung CT. Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2020;60(6):751\u20137. https:\/\/doi.org\/10.1002\/jcph.1573.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1101_CR100","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1038\/s41598-019-43746-x","volume":"9","author":"C-C Li","year":"2019","unstructured":"Li C-C, Wu S-T, Cha T-L, Sun G-H, Yu D-S, Meng E. A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan. Sci Rep. 2019;9(1):7240. https:\/\/doi.org\/10.1038\/s41598-019-43746-x.","journal-title":"Sci Rep"},{"issue":"2","key":"1101_CR101","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1600-0684.2005.00097.x","volume":"34","author":"C-Y Kim","year":"2005","unstructured":"Kim C-Y, Lee H-S, Han S-C, Heo J-D, Kwon M-S, Ha C-S, et al. Hematological and serum biochemical values in cynomolgus monkeys anesthetized with ketamine hydrochloride. J Med Primatol. 2005;34(2):96\u2013100. https:\/\/doi.org\/10.1111\/j.1600-0684.2005.00097.x.","journal-title":"J Med Primatol"},{"issue":"1","key":"1101_CR102","doi-asserted-by":"publisher","first-page":"39","DOI":"10.9740\/mhc.2017.01.039","volume":"7","author":"BJ Malcolm","year":"2017","unstructured":"Malcolm BJ, Lee KC. An ancient sacrament for treatment of contemporary psychiatric illness? Ment Health Clin. 2017;7(1):39\u201345. https:\/\/doi.org\/10.9740\/mhc.2017.01.039.","journal-title":"Ment Health Clin."},{"issue":"2","key":"1101_CR103","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5740\/jaoacint.16-0006","volume":"52","author":"V Van den Eynde","year":"2022","unstructured":"Van den Eynde V, Gillman PK, Blackwell BB. The prescriber\u2019s guide to the MAOI diet\u2014thinking through tyramine troubles. Psychopharmacol Bull. 2022;52(2):73\u2013116. https:\/\/doi.org\/10.5740\/jaoacint.16-0006.","journal-title":"Psychopharmacol Bull"},{"issue":"12","key":"1101_CR104","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268\u201378. https:\/\/doi.org\/10.1177\/0269881116662634.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1101_CR105","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","volume":"29","author":"P-\u00d8 Johansen","year":"2015","unstructured":"Johansen P-\u00d8, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270\u20139. https:\/\/doi.org\/10.1177\/0269881114568039.","journal-title":"J Psychopharmacol"},{"key":"1101_CR106","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00213-022-06086-9","volume":"239","author":"MM Pantoni","year":"2022","unstructured":"Pantoni MM, Kim JL, Van Alstyne KR, Anagnostaras SG. MDMA and memory, addiction, and depression: dose-effect analysis. Psychopharmacology. 2022;239:935\u201349. https:\/\/doi.org\/10.1007\/s00213-022-06086-9.","journal-title":"Psychopharmacology"},{"key":"1101_CR107","doi-asserted-by":"publisher","unstructured":"Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry. 2018;79(3):17m11634. https:\/\/doi.org\/10.4088\/JCP.17m11634.","DOI":"10.4088\/JCP.17m11634"},{"issue":"5","key":"1101_CR108","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1016\/j.biopsych.2016.08.041","volume":"82","author":"SJ Pennybaker","year":"2017","unstructured":"Pennybaker SJ, Luckenbaugh DA, Park LT, Marquardt CA, Zarate CA Jr. Ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects postinfusion. Biol Psychiatry. 2017;82(5):E35-E36. https:\/\/doi.org\/10.1016\/j.biopsych.2016.08.041.","journal-title":"Biol Psychiatry"},{"key":"1101_CR109","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","volume":"36","author":"JH Halpern","year":"2018","unstructured":"Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In:\u00a0Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behavioral Neurobiology of Psychedelic Drugs. Curr Top Behav Neurosci, vol 36. Berlin: Springer; 2018. pp. 333\u201360. https:\/\/doi.org\/10.1007\/7854_2016_457.","journal-title":"Curr Top Behav Neurosci"},{"issue":"2","key":"1101_CR110","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s0376-8716(02)00306-x","volume":"69","author":"JH Halpern","year":"2003","unstructured":"Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69(2):109\u201319. https:\/\/doi.org\/10.1016\/s0376-8716(02)00306-x.","journal-title":"Drug Alcohol Depend"},{"key":"1101_CR111","doi-asserted-by":"publisher","first-page":"1156319","DOI":"10.3389\/fnins.2023.1156319","volume":"17","author":"MM Urban","year":"2023","unstructured":"Urban MM, Stingl MR, Meinhardt MW. Mini-review: the neurobiology of treating substance use disorders with classical psychedelics. Front Neurosci. 2023;17:1156319. https:\/\/doi.org\/10.3389\/fnins.2023.1156319.","journal-title":"Front Neurosci"},{"issue":"9566","key":"1101_CR112","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369(9566):1047\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(07)60464-4.","journal-title":"Lancet"},{"key":"1101_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.newideapsych.2022.100967","volume":"67","author":"G Ona","year":"2022","unstructured":"Ona G, Kohek M, Bouso JC. The illusion of knowledge in the emerging field of psychedelic research. New Ideas Psychol. 2022;67: 100967. https:\/\/doi.org\/10.1016\/j.newideapsych.2022.100967.","journal-title":"New Ideas Psychol"},{"issue":"7","key":"1101_CR114","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","volume":"37","author":"OR Hovmand","year":"2023","unstructured":"Hovmand OR, Poulsen ED, Arnfred S, Storeb\u00f8 OJ. Risk of bias in randomized clinical trials on psychedelic medicine: a systematic review. J Psychopharmacol. 2023;37(7):649\u201359. https:\/\/doi.org\/10.1177\/02698811231180276.","journal-title":"J Psychopharmacol"},{"key":"1101_CR115","doi-asserted-by":"publisher","unstructured":"Dunlop BW, Medeiros Da Frota Ribeiro C. Randomized controlled trials and the efficacy of psychotropic medications. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2022. pp. 305\u201359. https:\/\/doi.org\/10.1007\/978-3-030-62059-2_4.","DOI":"10.1007\/978-3-030-62059-2_4"},{"issue":"9","key":"1101_CR116","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2023.1412","volume":"80","author":"L Colloca","year":"2023","unstructured":"Colloca L, Nikayin S, Sanacora G. The intricate interaction between expectations and therapeutic outcomes of psychedelic agents. JAMA Psychiat. 2023;80(9):867\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1412.","journal-title":"JAMA Psychiat"},{"key":"1101_CR117","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2018.00897","volume":"9","author":"ECHM Haijen","year":"2018","unstructured":"Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9:897. https:\/\/doi.org\/10.3389\/fphar.2018.00897.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1101_CR118","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133\u201352. https:\/\/doi.org\/10.1080\/17512433.2021.1933434.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1101_CR119","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268\u201383. https:\/\/doi.org\/10.1007\/s00213-006-0457-5.","journal-title":"Psychopharmacology"},{"issue":"9","key":"1101_CR120","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353. https:\/\/doi.org\/10.1001\/jama.2023.14530.","journal-title":"JAMA"},{"issue":"6","key":"1101_CR121","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239(6):1989\u20132010. https:\/\/doi.org\/10.1007\/s00213-022-06123-7.","journal-title":"Psychopharmacology"},{"key":"1101_CR122","doi-asserted-by":"publisher","unstructured":"Schenberg EE. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology. 2021;14(10):1317\u20131319. https:\/\/doi.org\/10.1080\/17512433.2021.1951473.","DOI":"10.1080\/17512433.2021.1951473"},{"issue":"3","key":"1101_CR123","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","volume":"11","author":"G Gr\u00fcnder","year":"2024","unstructured":"Gr\u00fcnder G, Brand M, Mertens LJ, Jungaberle H, K\u00e4rtner L, Scharf DJ, et al. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry. 2024;11(3):231\u20136. https:\/\/doi.org\/10.1016\/S2215-0366(23)00363-2.","journal-title":"Lancet Psychiatry"},{"key":"1101_CR124","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/7854_2021_298","volume":"56","author":"TL Golden","year":"2022","unstructured":"Golden TL, Magsamen S, Sandu CC, Lin S, Roebuck GM, Shi KM, et al. Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences, vol 56. Cham: Springer; 2022. pp. 35\u201370. https:\/\/doi.org\/10.1007\/7854_2021_298.","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"1101_CR125","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying harms is key to improving psychedelic-assisted therapy-participants call for changes to research landscape. JAMA Psychiat. 2023;80(5):411\u20132. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.0099.","journal-title":"JAMA Psychiat"},{"key":"1101_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.11.008","volume":"75","author":"T Lea","year":"2020","unstructured":"Lea T, Amada N, Jungaberle H, Schecke H, Klein M. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy. 2020;75: 102600. https:\/\/doi.org\/10.1016\/j.drugpo.2019.11.008.","journal-title":"Int J Drug Policy"},{"key":"1101_CR127","unstructured":"Winstock A, Munksgaard R, Davies E, Ferris J, Parris AZ, Barratt M. 2022 drug trend report: Time, music, clubbing, age, and diet. In: Global Drug Survey. 2022. https:\/\/www.globaldrugsurvey.com\/wp-content\/uploads\/2022\/02\/2022WowReport_Final.pdf. Accessed 01 Apr 2023."},{"issue":"3","key":"1101_CR128","doi-asserted-by":"publisher","first-page":"e2608","DOI":"10.1002\/hup.2608","volume":"32","author":"D Martins","year":"2017","unstructured":"Martins D, Barratt MJ, Pires CV, Carvalho H, Vilamala MV, Espinosa IF, et al. The detection and prevention of unintentional consumption of DOx and 25x-NBOMe at Portugal\u2019s Boom Festival. Hum Psychopharmacol. 2017;32(3):e2608. https:\/\/doi.org\/10.1002\/hup.2608.","journal-title":"Hum Psychopharmacol"},{"key":"1101_CR129","doi-asserted-by":"publisher","first-page":"204512532311984","DOI":"10.1177\/20451253231198466","volume":"13","author":"M van Elk","year":"2023","unstructured":"van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol. 2023;13:20451253231198464. https:\/\/doi.org\/10.1177\/20451253231198466.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1101_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.737738","volume":"12","author":"ML Williams","year":"2021","unstructured":"Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O\u2019Carroll S, et al. Translating psychedelic therapies from clinical trials to community clinics: building bridges and addressing potential challenges ahead. Front Psychiatry. 2021;12: 737738. https:\/\/doi.org\/10.3389\/fpsyt.2021.737738.","journal-title":"Front Psychiatry."},{"key":"1101_CR131","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/RMHP.S300656","volume":"14","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. The use of classic hallucinogens\/psychedelics in a therapeutic context: healthcare policy opportunities and challenges. Risk Manag Healthc Policy. 2021;14:901\u201310. https:\/\/doi.org\/10.2147\/RMHP.S300656.","journal-title":"Risk Manag Healthc Policy."},{"issue":"11","key":"1101_CR132","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/00048674221081763","volume":"56","author":"S Muthukumaraswamy","year":"2022","unstructured":"Muthukumaraswamy S, Forsyth A, Sumner RL. The challenges ahead for psychedelic \u201cmedicine.\u201d Aust N Z J Psychiatry. 2022;56(11):1378\u201383. https:\/\/doi.org\/10.1177\/00048674221081763.","journal-title":"Aust N Z J Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01101-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T07:21:35Z","timestamp":1725520895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01101-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"5 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Global Perspectives on Addictions and Drug Markets (Inter-GLAM), an international project, and co-funded by Grant No. 957776 under the European Union\u2019s Directorate General for Justice (DG Justice) Programme \u201cDrugs Policy Initiatives \u2013 Supporting initiatives in the field of drugs policy\u201d (JUST-2019-AG-DRUGS) from 1 July 2021 to 30 June 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data sharing is not applicable to this article, as no datasets were generated or analysed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Anton Gomez-Escolar: conceptualization, methodology, writing \u2013 original draft, writing \u2013 review and editing, supervision and project administration. Daniel Folch-Sanchez: conceptualization, methodology, writing \u2013 original draft and writing \u2013 review and editing. Joanna Stefaniuk: conceptualization, methodology, writing \u2013 original draft and writing \u2013 review and editing. Zoe Swithenbank: conceptualization, methodology, writing \u2013 original draft and writing \u2013 review and editing. Andreia Nisa: conceptualization, methodology and writing \u2013 original draft. Fleur Braddick: conceptualization, methodology, writing \u2013 review and editing and funding acquisition. Nazish Idrees Chaudhary: writing \u2013 review and editing. Pim B. van der Meer: conceptualization, methodology, writing \u2013 original draft and writing \u2013 review and editing. Albert Batalla: conceptualization, methodology, writing \u2013 review and editing and funding acquisition, supervision. All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}